| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526734 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2033
(9 years from now) | |
| US9808468 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2035
(11 years from now) | |
| US9649318 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2035
(11 years from now) | |
Vivlodex is owned by Iceutica Operations.
Vivlodex contains Meloxicam.
Vivlodex has a total of 3 drug patents out of which 0 drug patents have expired.
Vivlodex was authorised for market use on 22 October, 2015.
Vivlodex is available in capsule;oral dosage forms.
Vivlodex can be used as management of osteoarthritis pain by administering 10 mg of meloxicam; management of osteoarthritis pain by administering 5 mg of meloxicam.
The generics of Vivlodex are possible to be released after 31 March, 2035.
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam; Management of osteoarthritis pain by administering 5 mg of meloxicam
Dosage: CAPSULE;ORAL
VIVLODEX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic